2006
Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism
Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B. Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry 2006, 61: 545-550. PMID: 16730335, DOI: 10.1016/j.biopsych.2006.02.032.Peer-Reviewed Original ResearchConceptsRisperidone-induced increasesLong-term risperidone treatmentProlactin levelsRisperidone treatmentSerum prolactinOpen-label followWeeks of risperidoneBaseline prolactin levelsEffects of ShortPlacebo groupProlactin elevationReceptor polymorphismsWeek 8Baseline levelsMean increaseProlactinRisperidoneSerum samplesAdverse effectsPlaceboChildrenTreatmentMonthsDRD2 allelesAdolescents
2004
Effects of glucocorticoids on declarative memory function in major depression
Bremner J, Vythilingam M, Vermetten E, Anderson G, Newcomer J, Charney D. Effects of glucocorticoids on declarative memory function in major depression. Biological Psychiatry 2004, 55: 811-815. PMID: 15050862, DOI: 10.1016/j.biopsych.2003.10.020.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDeclarative memory functionVerbal declarative memory functionDay 3Major depressionMemory functionParagraph recallUnipolar major depressive disorderSubset of patientsEffects of glucocorticoidsHealthy human subjectsDepressive disorderTransient impairmentHealthy subjectsRandomized fashionDeclarative memoryGlucocorticoid receptorBrain regionsExogenous cortisolGlucocorticoidsPlaceboDexamethasonePatientsBaselineDepression
1998
A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome
Peterson B, Zhang H, Anderson G, Leckman J. A Double-Blind, Placebo-Controlled, Crossover Trial of an Antiandrogen in the Treatment of Tourette's Syndrome. Journal Of Clinical Psychopharmacology 1998, 18: 324-331.. PMID: 9690699, DOI: 10.1097/00004714-199808000-00013.Peer-Reviewed Original ResearchConceptsAndrogen receptor blockadeReceptor blockadeCrossover trialHormone levelsSyndrome patientsSelective androgen receptor antagonistAdult TS subjectsTreatment of ticsTourette syndrome patientsTic symptom severitySerious side effectsAndrogen receptor antagonistSymptom severity ratingsTS prevalenceClinic visitsFlutamide administrationEndocrine findingsObsessive-compulsive disorderReceptor antagonistAndrogen receptorPhysiologic compensationTherapeutic effectPhysiologic mechanismsSide effectsTourette syndrome
1997
A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome
Rasmusson A, Anderson G, Lynch K, McSwiggan-Hardin M, Scahill L, Mazure C, Goodman W, Price L, Cohen D, Leckman J. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biological Psychiatry 1997, 41: 117-121. PMID: 8988803, DOI: 10.1016/s0006-3223(96)00380-0.Peer-Reviewed Original Research
1994
Aspartame, behavior, and cognitive function in children with attention deficit disorder.
Shaywitz B, Sullivan C, Anderson G, Gillespie S, Sullivan B, Shaywitz S. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics 1994, 93: 70-5. PMID: 7505423, DOI: 10.1542/peds.93.1.70.Peer-Reviewed Original ResearchConceptsAttention deficit disorderWisconsin Card Sorting TestDeficit disorderTreatment Emergent Symptom ScalePlacebo-controlled crossover studyComplete blood cell countStudy centersLiver function testsUrinary excretion rateBlood cell countAdministration of aspartameMental Disorders criteriaCognitive testsMeasurement of catecholaminesCrossover studyFunction testsMonoamine metabolismInpatient admissionsMetabolite excretionLarge dosesSymptom ScaleUsual consumptionCell countPlasma phenylalanineBiochemical measures
1992
Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder
RIDDLE M, SCAHILL L, KING R, HARDIN M, ANDERSON G, ORT S, SMITH J, LECKMAN J, COHEN D. Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 1992, 31: 1062-1069. PMID: 1429406, DOI: 10.1097/00004583-199211000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildDouble-Blind MethodFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderPersonality AssessmentConceptsChildren's Yale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleEffective short-term treatmentSafety of fluoxetineFixed-dose trialCommon drug side effectsCY-BOCS total scoreMajor depressive disorderShort-term treatmentDrug side effectsMagnitude of improvementObsessive Compulsive ScaleFluoxetine groupPlacebo groupFluoxetine treatmentCrossover trialClinical trialsDepressive disorderObsessive-compulsive symptom severitySide effectsFluoxetineSymptom severityTotal scoreCompulsive Scale
1991
Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment
KING R, RIDDLE M, CHAPPELL P, HARDIN M, ANDERSON G, LOMBROSO P, SCAHILL L. Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment. Journal Of The American Academy Of Child & Adolescent Psychiatry 1991, 30: 179-186. PMID: 2016219, DOI: 10.1097/00004583-199103000-00003.Peer-Reviewed Original ResearchConceptsFluoxetine treatmentObsessive-compulsive disorderUniversity Clinical Research CenterClinical Research CenterMajor risk factorDrug-induced activationPrior suicidal ideationYounger patientsRisk factorsRegulation of aggressionPatientsSuicidal ideationSelf-destructive behaviorFluoxetineAge 10Apparent associationVulnerable individualsDisordersTreatmentIdeationDe novoHospitalizationSymptoms
1990
Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder
Shaywitz B, Shaywitz S, Sebrechts M, Anderson G, Cohen D, Jatlow P, Young J. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sciences 1990, 46: 625-633. PMID: 2308471, DOI: 10.1016/0024-3205(90)90131-a.Peer-Reviewed Original Research
1986
Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder.
Sebrechts M, Shaywitz S, Shaywitz B, Jatlow P, Anderson G, Cohen D. Components of attention, methylphenidate dosage, and blood levels in children with attention deficit disorder. Pediatrics 1986, 77: 222-8. PMID: 3945535, DOI: 10.1542/peds.77.2.222.Peer-Reviewed Original ResearchConceptsAttention deficit disorderDeficit disorderComponents of attentionDoses of methylphenidateCognitive resourcesCognitive componentsAttentional deficitsParent ratingsMethylphenidate dosageTest batteryMethylphenidateChildrenDisordersTaskDeficitsRatingsSingle testAttentionPerformanceTeachersBlood levelsBatteries
1983
Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure
LECKMAN J, DETLOR J, HARCHERIK D, YOUNG J, ANDERSON G, SHAYWITZ B, COHEN D. Acute and Chronic CLonidine Treatment in Tourette's Syndrome A Preliminary Report on Clinical Response and Effect on Plasma and Urinary Catecholamine Metabolites, Growth Hormone, and Blood Pressure. Journal Of The American Academy Of Child & Adolescent Psychiatry 1983, 22: 433-440. PMID: 6579101, DOI: 10.1016/s0002-7138(09)61504-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette syndromeHomovanillic acidHuman growth hormoneClinical responseBlood pressureGrowth hormoneΑ2-adrenergic receptor agonistTreatment of TSUrinary catecholamine metabolitesClinical response dataChronic neuropsychiatric disorderPlacebo-controlled conditionsA Preliminary ReportClonidine therapyOral clonidineNoradrenergic receptorsSingle doseUnknown etiologyFunctional statusReceptor agonistClinical trialsDopaminergic systemTS patients